PROSPECTIVE, MULTICENTRE, OBSERVATIONAL STUDY ON FATIGUE- AND HAND-FOOT SYNDROME-RELATED QUALITY OF LIFE IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA RECEIVING A TYROSINE KINASE INHIBITOR AS FIRST-LINE TREATMENT (TROYA STUDY)
Latest Information Update: 11 Nov 2021
At a glance
- Drugs Pazopanib (Primary) ; Sorafenib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms TROYA STUDY
- Sponsors Pfizer
- 30 Nov 2020 Status changed from active, no longer recruiting to completed.
- 26 May 2020 Planned End Date changed from 28 Feb 2020 to 30 Sep 2020.
- 26 May 2020 Planned primary completion date changed from 28 Feb 2020 to 30 Sep 2020.